To Evaluate Safety and the Pharmacokinetic Characteristics After Oral Administration of HT-003 Compared With Choline Alfoscerate Capsule in Healthy Adult Male Volunteers

NCT02395926 | Completed Phase 1

• 1 other identifier: HT-003-01
• Study Type: interventional
• Target: 24
• Locations: 0 countries
• Sites: N/A

Brief Summary

Choline alfoscerate(L-alfa glycerylphosphorylcholine) is a natural compound found in the brain and breast. Choline alfoscerate contains 40.8% of choline and has a produrig structure and separated by a precursor of choline and nerve cell membrane precursor of acetylcholine glycerophosphate. Choline alfoscerate Colin normalization of nerve pathways, nerve cell membrane play and acetylcholine receptor function secondary symptoms caused by cerebrovascular deficiency and indirectly through activation of metabolism, has a degenerative effect on the brain organic mental syndrome. Currently marketed oral choline alfoscerate received a geriatric cognitive impairment, secondary symptoms and degeneration, or soft capsule is authorized to prescription drugs for degenerative brain organic mental syndrome caused by cerebrovascular deficiency. Gliatilin soft capsules containing 400 mg per 1 capsule 2-3 times one days're supposed to take when considering optimal convenience and efficiency of the drug in patients with the development of sustained release formulations that can be maintained for a long period of time, a certain concentration is required. Accordingly, the modern drug by reducing the frequency of administration a day circuit is to develop a sustained release formulation of choline alfoscerate HT-003 600 mg medication compliance for the purpose of raising. 2 tablets at a time (600 mg x 2) can be taken one day to 1200 mg is required by taking. Therefore, for the development of sustained release formulation, the test in healthy adult male volunteers targets choline alfoscerate soft capsule formulation of 400mg 3 times per 1 day and sustained-release tablet 600mg 2time per 1 day, pharmacokinetic properties and safety of a single dose should be evaluated when compared.

Conditions

Healthy Male

Outcome Measures

Primary Outcomes (2)

• Cmax

  in 24hr after administration

• AUClast

  in 24hr after administration

Secondary Outcomes (3)

• baseline-corrected Cmax

  in 24hr after administration and before administration

• baseline-corrected AUClast

  in 24hr after administration and before administration

• Tmax

  in 24hr after administration and before administration

Study Arms (3)

R

ACTIVE COMPARATOR

Gliatilin soft capsule 400mg, administration 3 times per 1day 8:00 a.m., 14:00, 20:00

Drug: Gliatilin 400mg

T1

EXPERIMENTAL

HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00

Drug: Choline CR 600mg

T2

EXPERIMENTAL

HT-003 600mg\*2tab, administration 1 times per 1 day 8:00 a.m.

Drug: Choline CR 600mg

Interventions

Choline CR 600mg DRUG

HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00

T1

Gliatilin 400mg DRUG

Gliatilin soft capsule 400mg, administration 3 times per 1day 8:00 a.m., 14:00, 20:00

R

Eligibility Criteria

• Age: 20 Years - 55 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male subjects between the ages of 20 and 55 years, inclusive
• BMI\>=19kg/m2, \<=27kg/m2
• \*body mass index (kg/m2) = weight (kg)/ \[(height (m)2)
• Voluntary written consent by the parties that the ability and willingness to participate during the entire period of the test

You may not qualify if:

• Subjects who has history or clinically significant disease about liver, kidney, digestive, respiratory, musculoskeletal, endocrine, neuropsychiatric, blood•tumor type, cardiovascular disease.
• A GFR of less than 60ml/min person, calculated by the MDRD (Modification of Diet in Renal Disease)
• ※ MDRD equation (mL/min/1.73m2) : GFR = 175 x Scr-1.154 x age-0.203
• Systolic blood pressure less than 90 mmHg in vital signs is 150 mmHg or diastolic blood pressure less than 50 mmHg or higher or numerical characters shown equal to at least 100 mmHg
• Subjects with known for hypersensitivity reaction to components of the investigational drug
• Subjects who has history of drug abuse, shows positive in urine drug screening test
• Use of any prescription medication within 14 days prior to study medication dosing or use of any medication such as over-the-counter medication including oriental medication within 7 days prior to study medication dosing
• Participation in any clinical investigation within 60days prior to study medication dosing
• Subjects with whole blood donation within 60days, component blood donation within 30days
• Caffeine-containing beverages (coffee, tea, cola) intake or grapefruit / orange juice who exceed the average daily intake of 4 cups.
• Subjects who intake average alcohol consumption per week exceeds 140g or cannot be a non-alcohol during the hospital stay.
• Subjects who exceed the average daily smoke of 10 cigarettes or cannot be a non-smoking during the hospital stay
• Subjects who cannot limit the choline-containing food (liver, cocoa, bean, chocolate, otmil etc), from admitted to the hospital the day before
• Subjects who shows positive in serum test (hepatitis B, C, HIV)
• Subjects with decision of nonparticipation through investigator's review due to laboratory test results or other excuse such as non-responding to request or instruction by investigator

Sponsors & Collaborators

• Hyundai Pharmaceutical Co., LTD.: lead

Study Officials

• Jungryul Kim, Ph.D

  Samsung seoul hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 10, 2015
• First Posted: March 24, 2015
• Study Start: October 1, 2013
• Primary Completion: December 1, 2013
• Study Completion: December 1, 2013
• Last Updated: March 24, 2015

Record last verified: 2015-02